PubMed:23023453 JSONTXT

Annnotations TAB JSON ListView MergeView

{"target":"https://pubannotation.org/docs/sourcedb/PubMed/sourceid/23023453","sourcedb":"PubMed","sourceid":"23023453","source_url":"https://www.ncbi.nlm.nih.gov/pubmed/23023453","text":"Is US-guided core needle biopsy (CNB) enough in probably benign nodules with interval growth?\nPURPOSE: To investigate whether ultrasound-guided 14-gauge core needle biopsy (US-CNB) is efficient in the diagnosis of probably benign lesions showing interval growth on follow-up US. \nMATERIALS AND METHODS: From March 2008 to August 2009, 116 breast lesions in 113 women (mean age: 41.2 years, range: 19 - 63 years) which were initially assessed as category 3 showing interval growth on follow-up US underwent US-CNB, and subsequent US-guided vacuum-assisted excision, surgical excision or follow-up US for at least 12 months. Diagnostic performances of US-CNB were evaluated with histopathologic results and follow-up US as standard reference. Clinical features of the patient and lesions characteristics including follow-up interval (I), the most increased diameter (D), D per I, increased volume (%V) and %V per I were calculated and compared.\nRESULTS: Of the 116 lesions, 4 lesions were diagnosed as malignancy and 112 as benign on final pathology. Malignancy rate of probably benign lesions showing interval growth was 3.4 % (4/116). Incorrect biopsy rate was 0.9 % (1/116). Palpability or newly developed suspicious US features were more associated with malignancy, 75.0 to 13.4 % and 50.0 to 25.9 %, respectively, but without significance (p = 0.063 and 0.290). Significant differences were seen in average rank when comparing between benign and malignancy in D, %V, D per follow-up interval (I), and %V/I (p = 0.037, 0.017, 0.043 and 0.009, respectively).\nCONCLUSION: US-CNB is an efficient diagnostic method for probably benign lesions showing interval growth, with discordant biopsy rate of 0.9 %.","tracks":[{"project":"Allie","denotations":[{"id":"SS1_23023453_0_0","span":{"begin":13,"end":31},"obj":"expanded"},{"id":"SS2_23023453_0_0","span":{"begin":33,"end":36},"obj":"abbr"},{"id":"SS1_23023453_2_0","span":{"begin":126,"end":171},"obj":"expanded"},{"id":"SS2_23023453_2_0","span":{"begin":173,"end":179},"obj":"abbr"}],"relations":[{"id":"AE1_23023453_0_0","pred":"abbreviatedTo","subj":"SS1_23023453_0_0","obj":"SS2_23023453_0_0"},{"id":"AE1_23023453_2_0","pred":"abbreviatedTo","subj":"SS1_23023453_2_0","obj":"SS2_23023453_2_0"}],"attributes":[{"subj":"SS1_23023453_0_0","pred":"source","obj":"Allie"},{"subj":"SS2_23023453_0_0","pred":"source","obj":"Allie"},{"subj":"SS1_23023453_2_0","pred":"source","obj":"Allie"},{"subj":"SS2_23023453_2_0","pred":"source","obj":"Allie"}]}],"config":{"attribute types":[{"pred":"source","value type":"selection","values":[{"id":"Allie","color":"#ecd593","default":true}]}]}}